56 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
13 Mar 20
Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market
4:44pm
, the future results of preclinical and clinical studies, the research organization’s inability to recruit subjects and complete the Phase 2a study
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
27 Aug 20
Cocrystal Pharma Increases Previously Announced Bought Deal to $15.0 Million
6:02am
of preclinical and clinical studies, the research organization’s inability to recruit subjects and complete the Phase 2a study in a timely manner or at all
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
30 Oct 19
Cocrystal Pharma, Inc. Announces Proposed Underwritten Public Offering of Common Stock
5:09pm
inability to recruit subjects and complete the Phase 2a study in a timely manner or at all, including as the result of civil unrest and political
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
31 Oct 23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
8:00am
, the ability of our Clinical Research Organization partner to recruit volunteers for, and to proceed with, the Phase 2a clinical study for CC-42344
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
4 Mar 20
Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market
5:09pm
, the research organization’s inability to recruit subjects and complete the Phase 2a study in a timely manner or at all, including as the result
8-K
EX-99.1
1lrsyrlass1bm
27 Aug 20
Cocrystal Pharma Announces $10.0 Million Bought Deal Offering
12:00am
8-K
EX-99.1
4rl9vaekbtsy5f
5 May 21
Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock
7:52am
8-K
EX-99.1
l7vr21yd
10 Apr 23
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
8:30am
8-K
EX-99.1
iyfvvrgqko0
24 Apr 23
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors
8:13am
8-K
EX-99.1
hxgpjm 5i
26 Oct 22
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
8:00am
8-K
EX-99.1
0mr3oawvl9 b37
22 Dec 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
1onekhg ewl7331
11 May 22
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
8:30am
8-K
EX-99.1
dru 2naftf0l7ocnqc6
15 Nov 21
Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development
8:00am
8-K
EX-99.1
15an55we
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
8-K
EX-99.1
bbjgkhe4
23 Mar 22
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
4:05pm
8-K
EX-99.1
epczwr
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am
8-K
EX-99.1
o2q7b7 bbgo
15 Aug 22
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
8:00am
8-K
EX-99.1
pw1og0ntzbeqegyi0iq
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
8-K
EX-99.1
7tjr wzek6rk34
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm